Child and Adolescent Psychopharmacology Update

Psychiatric Clinics of North America

Volumn 32, Issue 1, 2009, Pages 111-133

  McVoy, Molly ^a   Findling, Robert ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anxiety; Autism; Medication; Mood disorder; Pediatric; Psychopharmacology; Treatment

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CYCLOSERINE; DEXAMPHETAMINE; ESCITALOPRAM; FLUOXETINE; GUANFACINE; HALOPERIDOL; LISDEXAMFETAMINE; LITHIUM; METHYLPHENIDATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADOLESCENT; ADOLESCENT DISEASE; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; CARDIOTOXICITY; CHILD; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISRUPTIVE BEHAVIOR; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HEADACHE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLEEP DISRUPTION; SOMNOLENCE; SUICIDAL IDEATION; TIC; WEIGHT GAIN;

ADOLESCENT; CHILD; HUMANS; MENTAL DISORDERS; PSYCHIATRY;

EID: 60549115441     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2008.11.002     Document Type: Review

References (163)

1. Kessler R.C., and Wang P.S. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 29 (2008) 115-129
2. Vitiello B. Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology 191 (2007) 5-13
3. Hoagwood K., Kelleher K., Feil M., et al. Treatment services for children with ADHD: a national perspective. J Am Acad Child Adolesc Psychiatry 39 2 (2000) 198-206
4. McClellan J.M., and Werry J.S. Evidence-based treatments in child and adolescent psychiatry: an inventory. J Am Acad Child Adolesc Psychiatry 42 12 (2003) 1388-1400
5. Pliska S., and AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J. Am Acad Child Adolesc Psychiatry 46 7 (2007) 894-921
6. Findling R. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Ther 30 5 (2008) 942-957
7. Swanson J., Wigal S., Wigal T., et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The COMACS study). Pediatrics 113 3 (2004) 206-216
8. Pelham W., Sturges J., Hoza J., et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 80 4 (1987) 491-501
9. Brown G., Ebert M., Mikkelse E., et al. Behavior and motor activity response in hyperactive children and plasma amphetamine levels following a sustained release preparation. J Am Acad Child Psychiatry 19 (1980) 225-239
10. Findling R., Bukstein O., Melmed R., et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69 (2008) 149-159
11. Wilens T., Boellner S., Lopez F., et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 47 6 (2008) 700-708
12. Wigal S., Swanson J., Fiefel D., et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43 11 (2004) 1406-1414
13. Muniz R., Brams M., Mao A., et al. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 15 3 (2008) 248-256
14. Biederman J., Boellner S., Childress A., et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62 (2007) 970-976
15. Du Y., Li F., Vance A., et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 42 9 (2008) 807-813
16. Gaffney G., Perry P., Lund B., et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J. Am Acad Child Adolesc Psychiatry 41 3 (2002) 330-336
17. Cummings D., Singer H., Krieger M., et al. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 25 6 (2002) 325-332
18. Kurlan R., Goetz C., McDermott M., et al. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58 (2002) 527-536
19. Biederman J., Melmed R., Patel A., et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121 1 (2008) 73-84
20. Carskadon M., Cavall A., Rosekind M., et al. Sleepiness and nap sleep following a morning dose of clonidine. Sleep 12 4 (1989) 338-344
21. Available at: www.fda.gov.
22. Available at: www.addrenex.com/lead_product.html.
23. Bambauer K., and Connor D. Characteristics of aggression in clinically referred children. CNS Spectr 10 9 (2005) 709-718
24. Nock M., Kaxdin A., Hiripi E., et al. Prevalence, subtypes, and correlates of DSM-IV conduct disorder in the National Comorbidity Survey replication. Psychol Med 36 5 (2006) 699-710
25. Findling R. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 69 Suppl 4 (2008) 9-14
26. Pappadopulos E., MacIntyre J., Crismon M., et al. Treatment recommendations for the use of antipsychotics for aggressive youth. J Am Acad Child Adolesc Psychiatry 42 2 (2003)
27. Steiner H., and Remsin L. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 46 1 (2007) 126-141
28. Findling R., Steiner H., Weller E., et al. Use of antipsychotics in children and adolescents. J Clin Psychiatry 66 Suppl 7 (2005) 29-40
29. Campbell M., Rapoport J., Simpson G., et al. Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 38 5 (1999) 537-545
30. Ruths S., and Steiner H. Psychopharmacologic treatment of aggression in children and adolescents. Pediatr Ann 33 5 (2004) 319-327
31. Campbell M., Small A., Green W., et al. Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41 7 (1984) 650-656
32. Malone R., Delaney M., Luebbert J., et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57 (2000) 649-654
33. Reyes M., Buitelaar J., Toren P., et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163 3 (2006) 402-410
34. Turgay A., Binder C., Snyder R., et al. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110 3 (2002) 1-12
35. Connor D., Fletcher K., Wood J., et al. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 62 12 (2001) 967-974
36. Biederman J., Mick E., Faraone S., et al. risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a Post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. Clin Therap 28 5 (2006) 794-800
37. Handen B., and Hardan A. Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry 45 8 (2006) 928-935
38. Masi G., Milone A., Canepa G., et al. Olanzapine treatment in adolescents with severe conduct disorder. Eur Psychiatry 21 (2006) 51-57
39. Kronenberger W., Giauque A., Lafata D., et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid attention-deficit/hyperactivity disorder, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol 17 3 (2007) 334-347
40. Findling R., Reed M., O'Riordan M., et al. A 26-week open-label study of quetiapine in children with conduct disorder. J Child and Adolesc Psychopharmacol 17 1 (2007) 1-9
41. Findling R., Reed M., O'Riordan M., et al. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 45 7 (2006) 792-800
42. Findling R, Blumer J, Kauffmann R, et al. Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder. Presented at the XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress. 2004.
43. Birmaher B., Brent D., et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 46 11 (2007) 1503-1526
44. Thase M., Nelson J., Papakostas G., et al. Augmentation strategies in the treatment of major depressive disorder. CNS Spectr 12 12 Suppl 22 (2007) 3-5
45. Geller B., Reisling D., Leonard H., et al. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 38 5 (1999) 513-516
46. Geller B., Cooper T., Graham D., et al. Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 31 1 (1992) 34-44
47. Birmaher B., Waterman S., Ryan N., et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. J Am Acad Child Adolesc Psychiatry 37 5 (1998) 527-535
48. Wilens T., Biederman J., Baldessarini R., et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 35 11 (1996) 1491-1501
49. Emslie G., Heiligenstein J., Wagner K., et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41 10 (2002) 1205-1215
50. Emslie G., Rush A., Weinberg W., et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54 11 (1997) 1031-1037
51. Emslie G., Heiligenstein J., Hoog S., et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43 11 (2004) 1397-1405
52. March J., Silva S., Vitiello B., et al. The treatment study for adolescents with depression study (tads): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 45 12 (2006) 1393-1403
53. March J., Silva S., Petrycki S., et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 292 7 (2004) 807-820
54. March J., Silva S., Petrycki S., et al. The treatment for adolescents with depression study (TADS). Arch Gen Psychiatry 64 10 (2007) 1132-1144
55. Brent D., Emslie G., Clarke G., et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 299 23 (2008) 901-913
56. Libby A., Brent D., Morrato E., et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 164 6 (2007) 884-891
57. Brent D. Antidepressants and pediatric depression-the risk of doing nothing. N Engl J Med 351 16 (2004) 1598-1601
58. Cheung A., Zuckerbrot R., Jensen P., et al. Guidelines for adolescent depression in primary care (GLAD-PC): II. Treatment and ongoing management. Pediatrics 120 5 (2007) 1313-1326
59. McClellan J., Kowatch R., Findling R., et al. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 46 1 (2007) 107-125
60. Findling R., Gracious B., McNamara N., et al. Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar 1 disorder. Bipolar Disord 3 (2001) 202-210
61. Smarty S., and Findling R. Psychopharmacology of pediatric bipolar disorder: a review. Psychopharmacology 191 (2007) 39-54
62. Findling R., Frazier J., Kafantaris V., et al. The collaborative lithium trials (CoLT): specific aims, methods, and implementation. Child Adolesc Psychiatry Ment Health. 2 21 (2008)
63. Kafantaris V., Coletti D., Dicker R., et al. Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. J Am Acad Child Adolesc Psychiatry 43 8 (2004) 984-993
64. Kafantaris V., Coletti D., Dicker R., et al. Lithium treatment of acute mania in adolescents: a large open trial. J Am Acad Child Adolesc Psychiatry 42 9 (2003) 1038-1045
65. Patel N., DelBello M., Bryan H., et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 45 3 (2006) 289-297
66. Available at: http://bpca.nichd.nih.gov/clinical/studies/index.cfm.
67. Kowatch R, Findling, R, Schefer R, et al. Pediatric bipolar collaborative mood stabilizer trial.
68. Wagner K., Redden L., Kowatch R., et al. Safety and efficacy of Divalproex ER in youth with mania (2007), AACAP
69. Findling R., McNamara N., Youngstrom E., et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 44 5 (2005) 409-417
70. Ginsberg L. Carbamazepine extended-release capsules: a retrospective review of its use in children and adolescents. Ann Clin Psychiatry 18 1 (2006) 3-7
71. Weisler R., Kalali A., Ketter T., et al. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 65 (2004) 478-484
72. Vieta E., Cruz N., Garcia J., et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacology 11 4 (2008) 445-452
73. Wagner K., Kowatch R., Emslie G., et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 163 7 (2006) 1179-1186
74. Delbello M., Findling R., Kushner S., et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44 6 (2005) 539-547
75. Wagner K., Nyilas M., Johnson B., et al. Long-term efficacy of aripiprazole in children (10-17 years old) with mania (2007), AACAP
76. Correll C., Auran C., Johsnon B., et al. Safety and tolerability of aripiprazole in children (10-17) with mania (2007), AACAP
77. DelBello M, Findling R, Earley W, et al. Efficacy of quetiapie in children and adolescents with bipolar mania: a 3-week, double-blind, randomized, placebo-controlled trial.
78. Pandina G., DelBello M., Kushner S., et al. Risperidone for the treatment of acute mania in bipolar youth (2007), AACAP
79. DelBello M, Findling R, Wang P, et al. Efficacy and safety of ziprasidone in pediatric bipolar disorder. APA Annual Meeting, 2008.
80. Tohen M., Kryzhanovskaya L., Carlson G., et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164 10 (2007) 1547-1556
81. Williams T., and Miller B. Pharmacologic management of anxiety disorders in children and adolescents. Curr Opin Pediatr 15 (2003) 483-490
82. Connoly S., Bernstein G., and Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 46 2 (2007) 267-283
83. Birmaher B., Axelson D., Monk K., et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 42 4 (2003) 415-423
84. Clark D., Birmaher B., Axelson D., et al. Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 44 12 (2005) 1263-1270
85. Cheer S., and Figgit D. Spotlight on fluvoxamine in anxiety disorders in children and adolescents. Paediatr Drugs 3 10 (2001) 763-781
86. Research Unit on Pediatric Psychopharmacology Anxiety Study Group (RUPP). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344 17 (2001) 1279-1285
87. Rynn M., Siqueland L., Rickels K., et al. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 158 12 (2001) 2008-2014
88. Wagner K., Berard R., Stein M., et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61 (2004) 1153-1162
89. March J., Entusah R., Rynn M., et al. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 62 (2007) 1149-1154
90. Rynn M., Riddle M., Yeung P., et al. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 164 (2007) 290-300
91. ClinicalTrials.gov.
92. Riddle M., Reeve E., Yaryura-Tobias J., et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40 2 (2001) 222-229
93. Geller D., Wagner K., Emslie G., et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 43 11 (2004) 1387-1396
94. Cook E., Wagner K., March J., et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 40 10 (2001) 1175-1181
95. March J., Biederman J., Wolkow R., et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280 20 (1998) 1752-1756
96. March J., Foa E., Gammon P., et al. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder; the pediatric OCD treatment study (POTS) randomized controlled trial. JAMA 292 16 (2004) 1969-1976
97. Freeman J., Garcia A., Fucci C., et al. Family-based treatment of early-onset obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 13 Suppl 1 (2003) 571-580
98. Perrin S., Smith P., Yule W., et al. Practitioner review: the assessment and treatment of post-traumatic stress disorder in children and adolescents. J Child Psychol Psychiatry 41 3 (2000) 277-289
99. Seedat S., Stein D., Ziervogel C., et al. Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. J Child Adolesc Psychopharm 12 1 (2002) 37-46
100. Porter D., and Bell D. The use of clonidine in post-traumatic stress disorder. J Natl Med Assoc. 91 8 (1999) 475-477
101. Harmon R., and Riggs P. Clonidine for posttraumatic stress disorder in preschool children. J Am Acad Child Adolesc Psychiatry 35 9 (1996) 1247-1249
102. Lustig S., Botelho C., Lynch L., et al. Implementing a randomized clinical trial on a pediatric psychiatric inpatient unit at a children's hospital: the case of clonidine for post-traumatic stress. Gen Hosp Psychiatry 24 (2002) 422-429
103. Stathis S., Martin G., McKenna J., et al. A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center. J Clin Psychopharmacol 25 6 (2005) 539-544
104. Famular R., Kinscherff R., Fenton T., et al. Propanolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. Am J Dis Child 142 11 (1988) 1244-1247
105. Diler R. Panic disorder in children and adolescents. Yonsei Med J 44 1 (2003) 174-179
106. Renaud J., Birmaher B., Wassick S., et al. Use of selective serotonin reuptake inhibitors for the treatment of childhood panic disorder: a pilot study. J Child Adolesc Psychopharm 9 2 (1999) 73-83
107. Leskovec T., Rowles B., Findling R., et al. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 16 2 (2008) 97-112
108. Aman M. Treatment planning for patients with autism spectrum disorders. J Clin Psychiatry 66 Suppl 10 (2005) 38-45
109. McDougle C., Kresch L., Posey D., et al. Repetitive thoughts and behaviors in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30 5 (2000) 427-435
110. Cook E., Rowlett R., Jaselskis C., et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 31 4 (1992) 739-745
111. Hollander E., Phillips A., Chaplin W., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharm 30 (2005) 582-589
112. Steingard R., Zimnitzky B., DeMaso D., et al. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharm Springfielder 7 1 (1997) 9-15
113. Hellings J., Kelley L., Gabrielli W., et al. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 57 8 (1996) 333-336
114. Owley T., Walton L., Sat J., et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 44 4 (2005) 343-348
115. Namerow L., Thomas P., Bostic J., et al. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 24 2 (2003) 104-108
116. Reminton G., Sloman L., Konstantareas M., et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharm 21 4 (2001) 440-444
117. Sanches L., Campbell M., Small A., et al. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 35 4 (1996) 537-544
118. DiMartino A., Melis G., Ciancehetti C., et al. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharm 14 2 (2004) 207-218
119. Handen B., Johnson C., Lubetsky M., et al. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30 3 (2000) 245-255
120. Research Units on Pediatric Psychopharmacology (RUPP). Randomized, Controlled, Crossover Trial of Methylphenidate in Pervasive Developmental Disorders with Hyperactivity.
121. Volkmar F., Cohen D., Hoshino Y., et al. Phenomenology and classification of the childhood psychoses. Psychol Med 18 1 (1988) 191-201
122. Campbell M., Fish B., David R., et al. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Child Schizophr 2 4 (1972) 343-358
123. Campbell M., Small A., Collins P., et al. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res Clin Exp 19 1 (1976) 70-86
124. Fankhauser M., Karumanchi V., German M., et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in children. J Clin Psychiatry 53 3 (1992) 77-82
125. Jaselskis C., Cook E., Fletcher K., et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12 5 (1992) 322-327
126. Posey D., Puntney J., Sasher T., et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharm 14 2 (2004) 233-241
127. Scahill L., Aman M., McDougle C., et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharm 16 5 (2006) 589-598
128. Research Units on Pediatric Psychopharmacology Autism Network (RUPP). Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162 7 (2005) 1361-1369
129. McDougle C., Scahill L., Aman M., et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162 6 (2005) 1142-1148
130. Aman M., Arnold E., McDougle C., et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharm 15 6 (2005) 869-884
131. Findling R., McNamara N., Gracious B., et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharm 14 2 (2004) 287-294
132. Martin A., Koenig K., Scahill L., et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharm 9 2 (1999) 99-107
133. Hollander E., Wasserman S., Swanson E., et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharm 16 5 (2006) 541-548
134. Kemner C., Willemsen S., deJonge M., et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharm 22 5 (2002) 455-460
135. Malone R., Cater J., Sheikh R., et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40 8 (2001) 887-894
136. Duggal H. Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. J Child Adolesc Psychopharm 17 2 (2007) 261-263
137. Cohen S., Fitzgerald B., Khan S., et al. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 65 (2004) 110-113
138. McDougle C., Kem D., Posey D., et al. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41 8 (2002) 921-927
139. Valicenti M., and Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharm 16 5 (2006) 549-560
140. Shastri M., Alla L., Sabaratnam M., et al. Aripiprazole use in individuals with intellectual disability and psychotic or behavioral disorders: a case series. J Psychopharm 20 6 (2006) 863-867
141. Hardan A., Jou R., Handen B., et al. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J Child and Adolesc Psychopharm 14 3 (2004) 426-432
142. Posey D., Kern D., Swiezy N., et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 161 11 (2004) 2115-2117
143. Danfors T., von Knorring A., Hartvig P., et al. Tetrahydrobiopterin in the treatment of children with autistic disorder. J Clin Psychopharm 25 5 (2005) 485-489
144. Kumra S., Oberstar J., Sikich L., et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophrenia Bulletin 34 1 (2008) 60-71
145. Correll C. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69 Suppl 4 (2008) 26-36
146. Thomas L., and Woods S. The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatment. Child Adolesc Psychiatr Clin N Am 15 (2006) 109-133
147. Sikich L., Frazier J., McLellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry AiA (2008) 1-13
148. Spencer E., Kafantaris V., Padron-Gayol M., et al. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 28 2 (1992) 183-186
149. Pool D., Bloom W., Mielki D., et al. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 19 1 (1976) 99-104
150. Realmuto G., Erickson W., Yellin A., et al. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 141 3 (1984) 440-442
151. Bishop J., and Pavuluri M. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatr Dis Treat 4 1 (2008) 55-68
152. Armenteros J., Whitaker A., Welikson M., et al. Risperidone in adolescents with schizophrenia: an open pilot study. Am J Acad Child Adolesc Psychiatry 36 5 (1997) 694-700
153. Mozes T., Ebert T., Michal S., et al. An open-label comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 16 4 (2006) 393-403
154. Zalsman G., Carmon E., Martin A., et al. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 13 3 (2003) 319-327
155. Gothelf D., Apter A., Reidman J., et al. Olanzapine, risperidone, and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 110 5 (2003) 545-560
156. van Bruggen J., Tijseen J., Dingemans P., et al. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol 18 6 (2003) 341-346
157. Findling R., Robb A., Nyilas M., et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry AiA (2008) 1-10
158. Kushner S., Unis A., Copenhaver M., et al. Acute and continuous efficacy and safety of risperidone in adolescents with schizophrenia (2007), AACAP
159. Kryzhanovskaya L, Schulz C, McDougle C, et al. Efficacy and safety of olanzapine in adolescents with schizophrenia: results from a double-blind, placebo-controlled trial. Presented at the 44th College of Neuropsychopharmacology.
160. Kranzler H., Kester H., Gerbino-Rosen G., et al. Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions. Child Adolesc Psychiatr Clin N Am 15 (2006) 135-159
161. Kumra S., Kranzler H., Gerbino-Rosen G., et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double blind comparison. Biol Psychiatry 63 5 (2008) 524-529
162. Kumra S., Frazier J., Jacobsen L., et al. Childhood onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53 12 (1996) 1090-1097
163. Shaw P., Sporn A., Gogtay N., et al. Childhood Onset Schizophrenia. A double-blind clozapine-olanzapine comparison. Arch Gen Psychiatry 63 (2006) 721-730